A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose-dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)

被引：0
|
作者：
Clarke, Jennifer [1 ]
Sul, Joohee [1 ]
DeAngelis, Lisa [1 ]
Lassman, Andrew [1 ]
Hormigo, Adilia [1 ]
Nolan, Craig [1 ]
Gavrilovic, Igor [1 ]
Gu, Bin [1 ]
Panageas, Kathy [1 ]
Abrey, Lauren [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
NEURO-ONCOLOGY | 2007年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：530 / 530
页数：1
相关论文
共 50 条
  • [31] Temozolomide plus 13-cis-retinoic acid (TMZ/cRA) as first-line chemotherapy for newly diagnosed glioblastoma multiforme (GBM): A retrospective study
    Penas-Prado, Marta
    Puduvalli, Vinay
    Groves, Morris
    Conrad, Charles
    Gilbert, Mark
    Levin, Victor A.
    Yung, W. K. Alfred
    NEURO-ONCOLOGY, 2007, 9 (04) : 523 - 523
  • [32] Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A. Quinn
    Sara Xiaoyin Jiang
    David A. Reardon
    Annick Desjardins
    James J. Vredenburgh
    Allan H. Friedman
    John H. Sampson
    Roger E. McLendon
    James E. Herndon
    Henry S. Friedman
    Journal of Neuro-Oncology, 2009, 95 : 393 - 400
  • [33] Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Quinn, Jennifer A.
    Jiang, Sara Xiaoyin
    Reardon, David A.
    Desjardins, Annick
    Vredenburgh, James J.
    Friedman, Allan H.
    Sampson, John H.
    McLendon, Roger E.
    Herndon, James E., II
    Friedman, Henry S.
    JOURNAL OF NEURO-ONCOLOGY, 2009, 95 (03) : 393 - 400
  • [34] Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
    Gilbert, Mark R.
    Wang, Meihua
    Aldape, Kenneth D.
    Stupp, Roger
    Hegi, Monika E.
    Jaeckle, Kurt A.
    Armstrong, Terri S.
    Wefel, Jeffrey S.
    Won, Minhee
    Blumenthal, Deborah T.
    Mahajan, Anita
    Schultz, Christopher J.
    Erridge, Sara
    Baumert, Brigitta
    Hopkins, Kristen I.
    Tzuk-Shina, Tzahala
    Brown, Paul D.
    Chakravarti, Arnab
    Curran, Walter J., Jr.
    Mehta, Minesh P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) : 4085 - +
  • [35] A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM)
    Brown, P. D.
    Krishnan, S.
    Sarkaria, J.
    Wu, W.
    Mischel, P.
    Yong, W. H.
    Arusell, R.
    Jenkins, R. B.
    Buckner, J. C.
    Giannini, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY
    Khasraw, Mustafa
    McDonald, Kerrie Leanne
    Rosenthal, Mark
    Lwin, Zarnie
    Ashley, David
    Wheeler, Helen
    Barnes, Elizabeth
    Foote, Matthew
    Koh, Eng-Siew
    Sulman, Erik
    Back, Michael
    Buckland, Michael
    Sim, Hao-Wen
    Fisher, Lauren
    Leonard, Robyn
    Hall, Merryn
    Yip, Sonia
    Simes, John
    NEURO-ONCOLOGY, 2019, 21 : 18 - 18
  • [37] Hypofractionated accelerated radiotherapy (HART) with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM)
    Mallick, Supriya
    Haresh, K. P.
    Gupta, Subhash
    Sharma, Seema
    Laviraj, M. A.
    Upadhyay, Ashish Dutt
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] AN AMERICAN BRAIN TUMOR CONSORTIUM (ABTC) PHASE I TRIAL OF ABT-888 (VELIPARIB), TEMOZOLOMIDE (TMZ), AND CONCURRENT RADIOTHERAPY (RT) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): HEMATOLOGIC TOXICITY IS LIMITING.
    Kleinberg, Lawrence
    Blakeley, Jaishri
    Mikkelsen, Tom
    Stevens, Glenn
    Ye, Xiaobu
    Ryu, Sam
    Desideri, Serena
    Desai, Bhardwaj
    Giranda, Vincent
    Grossman, Stuart
    NEURO-ONCOLOGY, 2012, 14 : 102 - 102
  • [39] SORAFENIB (SO) IN ASSOCIATION WITH LOW-DOSE METRONOMIC TEMOZOLOMIDE (TMZ) IN RECURRENT GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY RESULTS OF A PHASE II STUDY
    Landi, L.
    Zustovich, F.
    Galli, C.
    Lombardi, G.
    Galli, L.
    Amoroso, D.
    Porta, C.
    Fontana, A.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 330 - 331
  • [40] Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
    Athanassiou, H
    Synodinou, M
    Maragoudakis, E
    Paraskevaidis, M
    Verigos, C
    Misailidou, D
    Antonadou, D
    Saris, G
    Beroukas, K
    Karageorgis, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2372 - 2377
12345